Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Chr. Hansen Holding M&A Activity 2022

Dec 12, 2022

3357_rns_2022-12-12_172faa7b-2f67-450f-a713-92695067f547.html

M&A Activity

Open in viewer

Opens in your device viewer

Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner

Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner

DECEMBER 12, 2022 – ANNOUNCEMENT NO. 13

Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

Please see attachment.

CONTACT INFORMATION

Novozymes:



Investor Relations

Tobias Cornelius Björklund

+45 3077 8682

[email protected]
Chr. Hansen:



Investor Relations

Anders Mohr Christensen

+45 2515 2364

[email protected]
Press Relations

Lina Danstrup

+45 3077 0552

[email protected]
Press Relations

Sanne Seyer-Hansen

+45 6038 6207

[email protected]

Attachment